ArticleCancer science2019
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
217 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.International journal of clinical oncology · 2023Guideline
- Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.International journal of clinical oncology · 2023Guideline
- The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.Pathology international · 2021Guideline
- Guidelines for clinical evaluation of anti-cancer drugs.Cancer science · 2021Guideline
- Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System analysis suitability criteria: a single-arm, phase II clinical trial.Journal of gastroenterology · 2022Trial
- Trial
- Germline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor-normal paired sequencing study.International journal of clinical oncology · 2026Observational
- Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.Cancer science · 2026Article
- Article
- Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing.International journal of clinical oncology · 2026Article
- Role of pharmacists in providing information on cancer genome medicine and patient decision making: Open-label randomized controlled study.Exploratory research in clinical and social pharmacy · 2026Article
- Feasibility of Comprehensive Genomic Profiling for Biliary Tract Cancer Using Transpapillary Biopsy Samples: A Prospective Study.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasonography-Guided Tissue Acquisition.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Thoracic cancer · 2026Article
- Clinical significance of comprehensive genomic profiling in unresectable or recurrent gastrointestinal stromal tumors: a multicenter retrospective cohort study.Journal of gastroenterology · 2026Article
- Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.International journal of clinical oncology · 2026Article
- Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access.ESMO real world data and digital oncology · 2026Article
- Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer.Scientific reports · 2026Article
- Germline pathogenic variants detected by GenMineTOP: insight from a nationwide tumor/normal paired comprehensive genomic profiling test, in Japan.Journal of human genetics · 2026Article
157 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
Abstract
Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.